The present study confirmed that the PAM pathway is excessively activated in relapsed hormone receptor or ER positive breast cancer patients, suggesting that PAM pathway activation may contribute to the failure of endocrine treatment and that PAM pathway inhibitors may reverse endocrine therapy resistance, providing evidence for the combination of PAM pathway inhibitors and hormonal therapy. The gene discussed is NR4A1; the disease is breast cancer.